A new study conducted by researchers at the Medical Research Council’s Laboratory of Molecular Biology in Cambridge has resulted in a breakthrough in the understanding of how autoimmune responses can be controlled.

In a normal immune system, the body develops immune cells to recognize foreign material, like bacteria. Once encountered, the immune cells respond to eliminate the foreign material. Any rogue immune cells that would attack the body itself are destroyed during development or are regulated by special cell. A key gene in these regulatory cells is called Foxp3. Those people that either lack the Foxp3 gene or have a mutated version of the gene have dysfunctional immune regulation which can result in autoimmune diseases.

As a part of the study, scientists created a genetically engineered form of Foxp3 that can change developing immune cells into regulatory cells that have the ability to suppress immune response. They then injected the engineered gene into animals that were missing the Foxp3 gene.

Said group leader Dr. Alexander Betz: “When administered to and activated in animal models of arthritis, the modified cells inhibit or even reverse the disease process.”

The scientists are now working on determining the molecular mechanisms involved in the functioning of the Foxp3 gene and applying that to human cells. In that research they need to ensure that the human form of the gene does not negatively impact the body’s immune system.

“If Foxp3 functions as a key developmental switch in human immune cells, there is potential for a new avenue of therapy development that could transform arthritis treatment” — Dr. Betz.

The study was published in the current issue of the journal PLoS Biology.

Originally posted 2008-11-14 12:00:58. Republished by Blog Post Promoter

Social Bookmarks

Hide Sites

No related posts.

The FDA has received 30 reports of cancer in children under the age of 18 who had been treated for JIA with anti-TNF drugs along with other medications, such as methotrexate, or similar immunosuppressant drugs.

Nearly 50% of the reports state the patients developed Hodgkin’s and non-Hodgkin’s lymphoma. The other reports indicate development of melanoma, leukemia and solid organ cancers.

Besides rheumatoid arthritis, TNF blockers are used to treat psoriatic arthritis, Crohn’s disease, plaque psoriasis, ankylosing spondylitis, as well as other diseases. TNF blockers are know to result in inflammation and weakening of the immune system.

The manufacturers of these drugs have been directed by the FDA to provide information about all TNF blocker recipients who have developed cancer, and in some cases to track cancer reports for 10 years. The FDA has also requested the assistance of medical professionals and patients in reporting any side effects from TNF blockers through the MedWatch Adverse Event Reporting program at www.fda.gov/medwatch/report.htm.

Originally posted 2008-06-06 22:25:05. Republished by Blog Post Promoter

Social Bookmarks

Hide Sites

No related posts.

Recently a team of Spanish researchers, led by Dr Alberto Alonso-Ruiz has reviewed the findings of 13 clinical trials involving over 7,000 participants to compare anti-TNF to DMARDS. The team analyzed the data to determine the benefits and side effects of different doses of the drugs.

The team determined that all of the trials showed that, with the proper dose, anti-TNF were better for treating rheumatoid arthritis than drugs like methotrexate.

The research also pointed out, however, that those patients using anti-TNF drugs were more likely to complain of adverse side effects. In addition, patients that were using etanercept experienced the lowest withdrawal rates due to adverse events.

“Performing comparisons of new drugs is vital for measuring safety/efficacy relationships and monitoring adverse side-effects” said Dr. Alonzo-Ruiz.

Their research was published in the journal BMC Musculoskeletal Disorders.

Originally posted 2008-05-02 15:36:39. Republished by Blog Post Promoter

Social Bookmarks

Hide Sites

No related posts.

Baminercept was being investigated for use in RA patients who did not respond to treatment with conventional disease modifying anti-rheumatic drugs (DMARD), such as methotrexate. The primary endpoint was the measurement of patients who achieved a 50% improvement in the number of swollen, tender joints, as well as other clinical measures at week 14.

The secondary endpoints were defined as the proportion of patients with a 20% improvement and a 70% improvement in the number of swollen and tender joints as well as other quality of life measures.

The first Phase II study, known as 104RA202, included 380 patients with active rheumatoid arthritis did not have and adequate response to conventional DMARD therapy. This was a double-blind, placebo-controlled, multicenter trial designed to assess the efficacy of 5 different dosages of baminercept in combination with methotrexate over a 12 week period.

The second Phase II study, known as 104RA203, included about 120 patients with active RA that did not have an adequate response to tumor necrosis factor (TNF) inhibitors. This was also a randomized, double-blind, placebo-controlled, multicenter trial. It was designed to assess the efficacy of a 200 mg dose of baminercept over a 12 week period in combination with methotrexate.

Based on the results of these 2 trials, Biogen has decided to discontinue development of baminercept for treating rheumatoid arthritis. However, the company indicated that baminercept did have potential uses for treating other inflammatory diseases, such as Crohn’s disease and multiple sclerosis. As of now, there are no clinical trials scheduled for these conditions.

Originally posted 2008-10-23 11:36:26. Republished by Blog Post Promoter

Social Bookmarks

Hide Sites

No related posts.